{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-21-010086","form_type":"8-K","ticker":"PBSV","cik":"0001304161","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2021-09-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.563741+00:00","generated_at":"2026-06-29T03:47:09.418093+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pharma-Bio Serv Q3 revenue falls 20.5% YoY; net income boosted by $1.96M PPP forgiveness","bullets":["Revenue for Q3 $4.99M, down 20.5% YoY from $6.28M.","Net income $2.28M includes $1.96M PPP loan forgiveness; prior year $0.69M.","Nine-month revenue $14.5M vs $16.5M, down 12.2% YoY.","Company focused on M&A strategy and geographic expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-21-010086","json":"https://secwatch.observer/filing/0001654954-21-010086.json","markdown":"https://secwatch.observer/filing/0001654954-21-010086.md","text":"https://secwatch.observer/filing/0001654954-21-010086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1304161/000165495421010086/0001654954-21-010086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1304161/000165495421010086/pbsv_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T03:47:09.418093+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}